Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A dec exp |
| Therapy | Talazoparib |
| Indication/Tumor Type | ovarian cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A dec exp | ovarian cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Talzenna (talazoparib) in ovarian cancer cells in culture (PMID: 26069190). | 26069190 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26069190) | ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. | Full reference... |